Q32 Bio Restructures to Focus on Bempikibart's Development for Alopecia Areata, Discontinues ADX-097 Trial

Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced a corporate restr...

February 11, 2025 | Tuesday | News
Convergent Therapeutics Announces Promising Clinical Trial Updates for CONV01-α at ASCO Genitourinary Cancers Symposium 2025

Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment o...

February 11, 2025 | Tuesday | News
Eli Lilly's Omvoh® Achieves Long-Term Clinical and Endoscopic Outcomes in Crohn's Disease Patients in VIVID-2 Study

Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely acti...

February 10, 2025 | Monday | News
Genentech's Gazyva® Demonstrates Significant Improvement in Lupus Nephritis in Phase III REGENCY Trial

Genentech, a member of the Roche Group, announced that a detailed analysis of its Phase III REGENCY trial of Gazyva® (obinutuzumab) in people with acti...

February 10, 2025 | Monday | News
BioMed X and Merck Reveal Critical Insights on Extrachromosomal DNA in Cancer Paving the Way for Novel Therapies

The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal ...

February 06, 2025 | Thursday | News
NeuFit Revolutionizes Neurological Rehabilitation with Innovative NEUBIE Device

 NeuFit is revolutionizing neurological rehabilitation with its innovative approach that integrates advanced diagnostics and therapeutic technolo...

February 06, 2025 | Thursday | News
Partner Therapeutics Announces NEJM Publication of Phase 2 eNRGy Trial Results for Zenocutuzumab-Zbco (BIZENGRI®)

Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced  that the New England Journal of Medicine (NEJ...

February 06, 2025 | Thursday | News
Akeso, Inc. Completes Patient Enrollment in Global Phase III Trial Evaluating Ivonescimab for First-Line Treatment of Squamous NSCLC

 Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  is excited to announce the completion of patient enrollment in the global Phase III clini...

February 06, 2025 | Thursday | News
Kodiak Sciences to Present Novel Glaucoma Treatment at Glaucoma 360 New Horizons Forum 2025

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tre...

February 05, 2025 | Wednesday | News
Grifols Partners with FcR Therapeutics to Develop Nanobodies for Autoimmune Disease Treatment

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines,  announced that it is col...

February 05, 2025 | Wednesday | News
Roche Announces FDA Approval of Susvimo® for Diabetic Macular Edema, Offering a Treatment with Fewer Injections

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced  that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/...

February 05, 2025 | Wednesday | News
Vanda Pharmaceuticals and AnaptysBio Enter Exclusive Global License Agreement for Imsidolimab in GPP Treatment

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) announced an exclusive, global license agreement ...

February 04, 2025 | Tuesday | News
Halozyme's Subcutaneous RYBREVANT® Formulation Receives Positive CHMP Opinion for Advanced NSCLC Treatment

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a...

February 04, 2025 | Tuesday | News
PhaseV Partners with Alimentiv to Revolutionize GI Clinical Trials Using Machine Learning

 PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced  it has entered a strategic partnership with&...

February 04, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close